Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITI-1001 in Newly Diagnosed Glioblastoma
NCT05698199Phase 1Completed
- Sponsor
- Immunomic Therapeutics, Inc.
- Start
- Aug 2023
- Primary completion
- Feb 2026
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iti-1001 in glioblastoma (GBM), sponsored by Immunomic Therapeutics, Inc. Primary endpoints: Dose Limiting Toxicities at 2 years and Adverse Events and Serious Adverse Events at 2 years. Started Aug 2023; status: completed.
02
Drugs
iti-1001
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05698199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05698199.